Medicine ViiV Healthcare Reveals Positive Results from Phase I Trial for a Potential Longer-Acting HIV Treatment March 6, 2024March 6, 2024 admin Novel formulation of cabotegravir (CAB-ULA) allows for dosing intervals of at least four months. Share Facebook Twitter Pinterest Linkedin
